Search Results

You are looking at 1 - 10 of 561 items for :

  • "pathology" x
  • Refine by Access: All x
Clear All
Full access

Brian P. Rubin and John R. Goldblum

Fisher C Thomas JM . Accuracy of biopsy techniques for limb and limb girdle soft tissue tumors . Ann Surg Oncol 2001 ; 8 : 80 – 87 . 4. WHO classification of tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone . Lyon : IARC

Full access

Takashi Taketa, Kazuki Sudo, Arlene M. Correa, Roopma Wadhwa, Hironori Shiozaki, Elena Elimova, Maria-Claudia Campagna, Mariela A. Blum, Heath D. Skinner, Ritsuko U. Komaki, Jeffrey H. Lee, Manoop S. Bhutani, Brian R. Weston, David C. Rice, Stephen G. Swisher, Dipen M. Maru, Wayne L. Hofstetter, and Jaffer A. Ajani

primary EAC as determined by the residual cancer in the surgical specimen, 11 , 12 particularly after chemoradiation. 7 , 13 , 14 However, more detailed analysis with regard to surgical pathology stage (SPS), type of relapse, and timing of relapse has

Full access

Susan Lester

All breast carcinomas must originate within the ductal/lobular system as carcinoma in situ, but only a subset of these lesions progress to invasive carcinoma. Although pathologic evaluation of the extent of ductal carcinoma in situ (DCIS), the distance to margins, and the degree of margin involvement provides an estimation of the likelihood of residual disease, the amount of disease in the remaining breast cannot be predicted with certainty. Factors other than residual disease may be more important in determining whether patients with DCIS survive or succumb to breast cancer, including biologically new ipsilateral cancers, contralateral cancers, and the degree of resistance of the normal stroma to invasion.

Full access

Sanam Loghavi, Mark J. Routbort, Keyur P. Patel, Rajyalakshmi Luthra, Wei-Lien Wang, Russell R. Broaddus, Michael A. Davies, and Alexander J. Lazar

predictive of longer-term benefit with ipilimumab treatment, although the association trend is difficult to apply to individual patients due to overlapping ranges and needs further characterization. 47 , 48 The pathology community is fortunate to be at the

Full access

Matthias Holdhoff

“Molecular pathology in the context of classification of malignant gliomas has been an increasingly interesting, yet somewhat confusing, topic for many years,” said Matthias Holdhoff, MD, PhD, Associate Professor of Oncology and Neurosurgery

Full access

Gauri R. Varadhachary

clinical presentation suggestive of breast cancer (interestingly, autopsy studies suggest that a breast profile may be a rather uncommon CUP presentation). 11 In selected women with isolated axillary adenopathy, nonsquamous pathology, and a negative

Full access

Melissa Magrath, Edward Yang, Chul Ahn, Christian A. Mayorga, Purva Gopal, Caitlin C. Murphy, Samir Gupta, Deepak Agrawal, Ethan A. Halm, Eric K. Borton, Celette Sugg Skinner, and Amit G. Singal

Pathology Reporting and Clinical Decision Support System (CoRS) in December 2013. CoRS is a user-friendly, EMR-based template that captures data from colonoscopy and pathology reports and uses a computerized algorithm to generate tailored, guideline

Full access

Benjamin O. Anderson and Robert W. Carlson

limited-resource countries: diagnosis and pathology . Breast J 2006 ; 12 ( suppl 1 ): S27 – 37 . 26. Anderson BO Yip CH Ramsey SD . Breast cancer in limited-resource countries: health care systems and public policy . Breast J 2006 ; 12

Full access

Daniel G. Coit, Robert Andtbacka, Christopher J. Anker, Christopher K. Bichakjian, William E. Carson III, Adil Daud, Raza A. Dilawari, Dominick DiMaio, Valerie Guild, Allan C. Halpern, F. Stephen Hodi Jr., Mark C. Kelley, Nikhil I. Khushalani, Ragini R. Kudchadkar, Julie R. Lange, Anne Lind, Mary C. Martini, Anthony J. Olszanski, Scott K. Pruitt, Merrick I. Ross, Susan M. Swetter, Kenneth K. Tanabe, John A. Thompson, Vijay Trisal, and Marshall M. Urist

considered. Pathology Report In the revised American Joint Committee of Cancer (AJCC) staging system, patients with melanoma are categorized into 3 groups: localized disease with no evidence of metastases (stage I–II), regional disease (stage III

Full access

Presenter: Julio M. Pow-Sang

Although localized prostate cancer is a heterogeneous disease, certain diagnostic features—pathology, imaging, and genetic profiling—can be helpful in categorizing patients into risk groups for adverse outcomes. At the NCCN 2022 Annual Conference